Tags

Type your tag names separated by a space and hit enter

[Premature ejaculation].
Urologe A. 2009 Jun; 48(6):663-74.U

Abstract

With prevalence rates of 20%-25% premature ejaculation (PE) represents the most frequent sexual dysfunction in men. Whereas genetically determined changes in the serotonin receptor-/transporter mechanism seem to be responsible for lifelong PE, acquired PE is often associated with other conditioning diseases such as erectile dysfunction, prostatitis or thyroid dysfunctions. Typical features of PE are a short intravaginal ejaculatory latency time (IELT) <1-2 min, lack of control over ejaculation, personal distress and partner problems. Treatment of PE subdivides into sexual therapy as well as drug therapy. Among the medications considered for PE, oral therapy with selective serotonin re-uptake inhibitors (SSRI), Dapoxetine (the first officially approved medication for PE) and topical therapy with lidocaine/prilocaine-containing medications are given priority.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Porst H
Porst20354@aol.com

MeSH

Anesthetics, LocalBenzylaminesEjaculationHumansLidocaineMaleMarital TherapyNaphthalenesPrilocaineSerotonin Uptake InhibitorsSexual Dysfunction, Physiological

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

19557470

Citation

Porst, H. "[Premature Ejaculation]." Der Urologe. Ausg. A, vol. 48, no. 6, 2009, pp. 663-74.
Porst H. [Premature ejaculation]. Urologe A. 2009;48(6):663-74.
Porst, H. (2009). [Premature ejaculation]. Der Urologe. Ausg. A, 48(6), 663-74. https://doi.org/10.1007/s00120-009-2019-z
Porst H. [Premature Ejaculation]. Urologe A. 2009;48(6):663-74. PubMed PMID: 19557470.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Premature ejaculation]. A1 - Porst,H, PY - 2009/6/27/entrez PY - 2009/6/27/pubmed PY - 2009/9/24/medline SP - 663 EP - 74 JF - Der Urologe. Ausg. A JO - Urologe A VL - 48 IS - 6 N2 - With prevalence rates of 20%-25% premature ejaculation (PE) represents the most frequent sexual dysfunction in men. Whereas genetically determined changes in the serotonin receptor-/transporter mechanism seem to be responsible for lifelong PE, acquired PE is often associated with other conditioning diseases such as erectile dysfunction, prostatitis or thyroid dysfunctions. Typical features of PE are a short intravaginal ejaculatory latency time (IELT) <1-2 min, lack of control over ejaculation, personal distress and partner problems. Treatment of PE subdivides into sexual therapy as well as drug therapy. Among the medications considered for PE, oral therapy with selective serotonin re-uptake inhibitors (SSRI), Dapoxetine (the first officially approved medication for PE) and topical therapy with lidocaine/prilocaine-containing medications are given priority. SN - 1433-0563 UR - https://www.unboundmedicine.com/medline/citation/19557470/[Premature_ejaculation]_ L2 - https://dx.doi.org/10.1007/s00120-009-2019-z DB - PRIME DP - Unbound Medicine ER -